Online inquiry

IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3214MR)

This product GTTS-WQ3214MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD70 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001252.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 970
UniProt ID P32970
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3214MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7270MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ112MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ4266MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ3950MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ2392MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 110
GTTS-WQ10066MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ482MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ13527MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW